

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
PARTNER OBLENIO DOSES FIRST PATIENTS IN PHASE IA
TRIAL OF LBL-051 FOR REFRACTORY AUTOIMMUNE DISEASES
AND
SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that its NewCo^{Note} with Aditum Bio, Oblenio Bio (“**Oblenio**”), has dosed first patients in the Phase Ia first-in-human clinical trial in Europe of its sole asset LBL-051, a trisppecific T-cell engager targeting BCMA, CD19 and CD3.

LBL-051 is designed to safely induce complete depletion of B cells and plasma cells for a durable immune system reset and the potential for sustained drug-free remission in patients with autoimmune diseases. Preclinical data have shown that LBL-051 achieves complete depletion of both B cells and plasma cells through dual targeting of CD19 and BCMA, with minimal cytokine release.

The open-label, multicenter Phase Ia study is enrolling patients with refractory autoimmune diseases across multiple indications. Utilizing a subcutaneous dosing regimen, the trial evaluates safety, tolerability, clinical response, B cell and plasma cell depletion in blood and tissue and select biomarkers. The study design, which received approval from the Paul Ehrlich Institute (PEI), employs a highly innovative first-in-human dose-escalation scheme that enables rapid and thoughtful evaluation of this off-the-shelf therapeutic approach, generating proof-of-concept data while prioritizing patient safety in a range of autoimmune diseases.

This milestone underscores the proven ability of the Company's proprietary LeadsBody™ platform to generate differentiated, globally competitive assets. Following the clinical validation of LBL-034 in hematological malignancies, LBL-051 is now advancing into autoimmune diseases – a broad application area for TCE technology – with the potential for further clinical validation. As the originating innovator, the Company continues to provide technical support to Oblenio and remains eligible for significant milestone payments and royalties as LBL-051 advances through global clinical development and commercialization.

Note

In November 2024, we entered into a collaboration, exclusive option and license agreement with Oblenio Bio, Inc. (“**NewCo**”), a U.S. company formed by Aditum Bio Fund 3, L.P. (“**Aditum Bio**”). Under the agreement, we grant NewCo an exclusive, worldwide license to develop, manufacture and commercialize LBL-051, subject to NewCo's exercise its option following the applicable option period.

About LBL-051

LBL-051 was discovered and engineered using the Company's proprietary LeadsBody™ platform. By simultaneously targeting BCMA, CD19 and CD3, LBL-051 is uniquely designed to deplete a broader spectrum of pathogenic B-cell and plasma cell populations, offering the potential for deeper and more durable responses compared to single-target or bispecific approaches. This immune reset strategy aims to achieve long-term drug-free remission for patients suffering from a range of refractory autoimmune diseases.

Preclinical data presented by Oblenio at the 2026 European Congress of Rheumatology (EULAR 2026) demonstrated that step-up dosing of LBL-051 resulted in complete depletion of peripheral and tissue B-cells and plasma cells in non-human primates, with consequent emergence of immature, non-memory B-cells in the blood upon recovery – findings consistent with changes described in autoimmune patients achieving long-lasting drug-free remissions in the clinic. Importantly, the study showed that the treatment did not cause cytokine release syndrome (CRS), including at high exposure levels, and demonstrated dose-dependent decreases in peripheral blood immunoglobulins, consistent with plasma cell depletion.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-051, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of the Company dated July 1, 2026 (the “**Announcement**”) in relation to the grant of Awards pursuant to the H Share Award Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to provide shareholders and potential investors of the Company with additional information in relation to the grant of Awards as follows:

Among the Grantees, Mr. Zuo is an executive Director and thus he is a connected person of the Company under Chapter 14A of the Listing Rules. No new Shares will be allotted and issued upon vesting and settlement of such Awards. Accordingly, the grant of the Awards to Mr. Zuo constituted a connected transaction of the Company under Chapter 14A of the Listing Rules. As the grant of Awards to Mr. Zuo forms part of the remuneration package under his service agreement with the Group, such grant is therefore exempted from the reporting, announcement and independent Shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

Save as disclosed above, all other information and contents set out in the Announcement remain unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, August 4, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.